BeiGene (BGNE)

• Market cap: $19.4B
• 1 day: 0.04%
• 5 days: 1.87%
• 1 month: -11.56%
• 3 months: -18.95%
• 6 months: 25.59%
• Year to date: 2.81%
• 1 year: 2.81%
• 5 years: 9.36%
• 10 years: 542.55%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Employees: 10,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

142% more call options, than puts

Call options by funds: $66.1M | Put options by funds: $27.3M

86% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 29

56% more capital invested

Capital invested by funds: $6.69B [Q2] → $10.4B (+$3.73B) [Q3]

25% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]

13% more funds holding

Funds holding: 197 [Q2] → 222 (+25) [Q3]

0.03% less ownership

Funds ownership: 3.75% [Q2] → 3.72% (-0.03%) [Q3]

38% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 84

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $235 29% upside
• Avg. target: $265 46% upside
• High target: $300 65% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Sean Laaman 0% 1-year accuracy 0 / 1 met price target	65% upside $300	Overweight Assumed	3 Dec 2024
TD Cowen Yaron Werber 56% 1-year accuracy 10 / 18 met price target	43% upside $260	Buy Maintained	13 Nov 2024
JP Morgan Jessica Fye 46% 1-year accuracy 19 / 41 met price target	29% upside $235	Overweight Maintained	22 Oct 2024